— Know what they know.
Not Investment Advice

OWCP OTC

OWC Pharmaceutical Research Corp.
1W: +900.0% 1M: +0.0% 3M: +900.0% YTD: +0.0% 1Y: +0.0% 3Y: -99.9% 5Y: -100.0%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 48 · $4975 mcap · 497M float · 0.0000% daily turnover

Balance Sheet Trends

Total Assets
$4M +234.8% ▲
5Y CAGR: +328.2%
Total Liabilities
$13M +4703.6% ▲
5Y CAGR: +151.9%
Shareholders Equity
-$9M -1294.0% ▼
Cash & Investments
$3M +256.9% ▲
5Y CAGR: +326.0%
Total Debt
$0 +0.0% ▲
Net Debt
-$3M -256.9% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2014FY2015FY2016FY2017FY2018
— Assets —
Cash$1M$357K$472K$971K$3M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$1M$357K$472K$971K$3M
Net Receivables$0$12K$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$24K$0$8K$74K$52K
Total Current Assets$1M$408K$482K$1M$4M
Property, Plant & Equip.$29K$23K$15K$16K$37K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$652K$1M$869K$360K
Other Non-Current Assets$0-$652K-$1M-$869K-$360K
Total Non-Current Assets$29K$23K$15K$16K$37K
Total Assets$2M$430K$497K$1M$4M
— Liabilities —
Accounts Payable$17K$28K$8K$37K$98K
Short-Term Debt$0$3K$0$0$0
Deferred Revenue$0$50K$100K$100K$100K
Other Current Liabilities$0$26K$38K$133K$240K
Total Current Liabilities$60K$108K$146K$270K$438K
Long-Term Debt$0$0$250K$0$0
Other Non-Current Liab.$0$0$0$0$13M
Total Non-Current Liabilities$0$0$250K$0$13M
Total Liabilities$60K$108K$396K$270K$13M
— Equity —
Common Stock$784$815$1K$1K$2K
Retained Earnings-$6K-$8M-$10M-$15M-$27M
Accumulated OCI-$6M-$8M$6K$6K$3K
Total Stockholders Equity$1M$323K$101K$791K-$9M
Total Liabilities & Equity$2M$430K$497K$1M$4M
— Key Metrics —
Total Debt$0$3K$250K$0$0
Net Debt-$1M-$354K-$222K-$971K-$3M
Total Investments$0$652K$1M$869K$360K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms